November 21, 2013 -- credentis ag was presented the prestigious Swiss Technology Award 2013 at the Swiss Innovation Forum in Basel. The Innovation of Curolox® Technology and its realisation in Curodont™ Repair convinced the Expert Group. The laudations mentioned specifically the progress in tooth preservation made possible by Curodont™ Repair. “The Swiss Technology Award is a great achievement for us. Independent experts validate its innovation and market viability. The Award rewards our courage to focus on this technology and its potential,“ says Michael Hug, CTO credentis ag. Link to the company presentation (German)
About Curodont™ and the Curolox™ Technology
The patented Curolox® Technology is based on peptides self-assembling into a 3-dimensional matrix, triggering biomimetic mineralisation and repair. The core technology is the basis for all innovative credentis products.
Curodont™ Repair provides dentists with a non-invasive option for natural mineralisation rather than classical repair of carious lesions. Applied to an early lesion, Curodont™ Repair forms a scaffold within the lesion to allow new hydroxyapatite (tooth mineral) crystals to form and grow. Ideally, the lesion will mineralise within several weeks. This effect is observed in a growing number of patients both in clinical studies and daily practice settings. Curodont™ Repair shows tremendous potential in the treatment of early dental caries.
Curodont™ Protect uses the Curolox® Technology to protect the tooth surface from acid attack and to treat unpleasant tooth sensitivity. According to CEO, Dominik Lysek, “Curodont™ Protect has its main benefit in prophylaxis and in the treatment of dentin hypersensitivity.”
credentis, with its regenerative product line, supports the trend towards prevention and early treatment. The ultimate goal is to prevent caries through the use of its regenerative solutions, and frequent recalls by dentists and hygienists.
About credentis ag
credentis ag is headquartered in the Technopark, Aargau, Switzerland. credentis has won multiple awards as well as support from organizations such as Genilem. Public grants include Swiss National Fund, Aargauer Forschungsfond in collaboration with the FHNW School of Life Sciences in Muttenz and the Medical Technologies IKC with the University of Leeds.
Dr. Dominik Lysek, CEO; Michael Hug, CTO; and Tobias Feger, CBO, have a strong track record in medical technology, marketing and networking in the dental industry. credentis board members Dr. Werner Berner, Dr. Michael Peetz and Dr. Erich Platzer (chairman), contribute their pharma, medtech and dental industry expertise.
Help employers find you! Check out all the jobs and post your resume.
